Clinical trials: Hospitalized COVID-19
Anorexia Nervosa
Care in Patients Hospitalized for Anorexia Nervosa at the Time of the Coronavirus-19 Epidemic (QUALICOVID)
Anorexia nervosa is a severe psychiatric condition. On the nutritional level, one of the objectives recommended by the High Authority of Health is to "achieve and maintain an appropriate weight and nutritional status".
- Trial name
- QUALICOVID (NCT04387708)
- Where
- France
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Centre Psychothérapique de Nancy
Covid19
Impact of Colchicine and Low-dose Naltrexone on COVID-19
The purpose of this study is to explore the impact of two medications-colchicine and low-dose naltrexone (LDN)-relative to standard of care (SOC) on COVID-19 disease progression to severe/critical illness and/or intubation in…
- Trial name
- COLTREXONE (NCT04756128)
- Testing
- Colchicine 0.6 mg, Naltrexone
- Where
- 2 sites in United States
- Volunteers
- 142 people
- Sponsor
- HealthPartners Institute
COVID-19
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
- Trial name
- NCT05387369
- Testing
- Paxlovid
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Huashan Hospital
ARDS, Human, Covid19
Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset
The mortality rates associated with COVID-19 related ARDS (COVIDARDS) have varied from observational reports from around the world.
- Trial name
- NorthCARDS (NCT04729075)
- Testing
- ARDS and COVID19 treatments
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- Northwell Health
Covid19
Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19
Primary objectives Part 1: To evaluate the safety and tolerability of COR-101 compared to placebo Secondary objectives Part 1: To evaluate the preliminary efficacy of COR-101 compared to placebo in hospitalized patients with…
- Trial name
- NCT04674566
- Testing
- COR-101
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Corat Therapeutics Gmbh
Covid19
Novaferon in Non-hospitalized Adult Patients With Mild COVID-19
An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients with Mild COVID-19
- Trial name
- NCT05172037
- Testing
- Novaferon
- Where
- Japan
- Volunteers
- 222 people
- Sponsor
- Genova Inc.
Severe Acute Respiratory Syndrome Coronavirus 2
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
This trial is designed to determine if the inflammation modulating effect of vagus nerve stimulation can improve pulmonary function and limit progression to ARDS in hospitalized COVID-19 hospitalized patients.
- Trial name
- NCT04379037
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation
- Where
- Argentina
- Volunteers
- 50 people
- Sponsor
- Nemechek Technologies
COVID19, SARS-CoV-2 Infection
Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO
The overall objective of the study is to determine the therapeutic effect and tolerance of Sarilumab in combination with Azithromycin and Hydroxychloroquine, compared to Sarilumab only, patients with moderate, severe pneumonia…
- Trial name
- CORIMUNO-VIRO (NCT04341870)
- Testing
- Sarilumab, Azithromycin, Hydroxychloroquine
- Where
- 5 sites in France
- Volunteers
- 27 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 1 Diabetes, Covid19
Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic in Egypt
Although reports showed that children with well controlled diabetes do not appear to have increased risk of infection with SARS-CoV-2, however data are scarce regarding the extent to which clinical and demographic data of patient…
- Trial name
- NCT04536285
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Ain Shams University
COVID-19 Pneumonia
IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.
The aim of the current clinical study is to evaluate the efficacy and safety of inhibition of Interleukin-1 receptor associated kinase 4 (IRAK4) in ameliorating the proinflammatory state and improving outcomes in severe COVID-19.
- Trial name
- NCT04933799
- Testing
- PF-06650833
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Giovanni Franchin, M.D, Ph.D
Covid19
Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia
Tofacitinib suppresses pro-inflammatory signaling that may be important pathogenetically to progression to more severe lung disease and acute respiratory distress syndrome (ARDS) in patients with COVID-19.
- Trial name
- NCT04469114
- Testing
- Tofacitinib 10 mg
- Where
- 17 sites in Brazil
- Volunteers
- 289 people
- Sponsor
- Hospital Israelita Albert Einstein
COVID-19
Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients
The primary objective of this study is to evaluate the safety and efficacy of intravenous (IV) infusion of ulinastatin compared to placebo with respect to time to recovery, disease severity, need for ventilator support, and…
- Trial name
- NCT04393311
- Testing
- Ulinastatin
- Where
- United States
- Sponsor
- Stanford University
Covid19, SARS-CoV-2 Infection
Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
This is a randomized, open-label, controlled, Phase II proof of concept study to evaluate the safety, tolerability and efficacy of S-1226 in which hospitalized subjects (n≤30) with moderate severity COVID-19…
- Trial name
- NCT04738136
- Testing
- S-1226
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- SolAeroMed Inc.
Pneumonia, Viral
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
The study objective is to assess Efficacy and safety of Reparixin treatment as compared to placebo (both on top of standard treatment) in adult patients with severe COVID-19 pneumonia.
- Trial name
- NCT04878055
- Testing
- Reparixin
- Where
- 17 sites in United States, Italy
- Volunteers
- 287 people
- Sponsor
- Dompé Farmaceutici S.p.A
Coronavirus Infection, Coronavirus
Convalescent Plasma for Patients With COVID-19
Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in patients with COVID-19 respiratory disease.
- Conditions
- Coronavirus Infection, Coronavirus, COVID
- Trial name
- NCT04385199
- Testing
- Convalescent plasma
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Henry Ford Health System
Covid19
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
- Trial name
- ACTIV-4A (NCT04505774)
- Testing
- theraputic heparin, prophylactic heparin, P2Y12
- Where
- 101 sites in United States, Brazil and 2 more
- Volunteers
- 3,591 people
- Sponsor
- Matthew Neal MD
SARS CoV 2 Infection
Nosocomial COVID-19 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021
The rate of nosocomial SARS-CoV2 infections found in the different studies since the beginning of the pandemic is very variable (<1% in hospitals in the USA to about 20% in a British hospital).
- Trial name
- COVIDIN (NCT05567874)
- Testing
- Nosocomial SARS-COV 2 Infection proportion
- Where
- France
- Volunteers
- 216 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Viral Pneumonia
Multiplex PCR for Severe Respiratory Infections During the COVID-19 Pandemic
The hypothesis was that a retrospective investigation of the molecular virological tests in a University hospital could be informative, with the aim to identify non-COVID-19 respiratory viruses during the circulation of…
- Trial name
- VirCoV+ (NCT06349707)
- Testing
- other: Observational
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Central Hospital, Nancy, France
COVID-19
Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients
General objective of the study To assess the efficacy and safety of enoxaparin in hospitalized patients with moderate to severe COVID-19 (Coronavirus Disease 2019) infection.
- Trial name
- INHIXACOV19 (NCT04427098)
- Testing
- Enoxaparin 40 Mg/0.4 mL Injectable Solution, Enoxaparin
- Where
- 13 sites in Italy
- Volunteers
- 301 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Viral Disease
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
- Trial name
- NCT04535167
- Testing
- PF-07304814
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 26 people
- Sponsor
- Pfizer